Kamada Ltd., a specialty biopharmaceutical company focused on plasma-derived therapeutics, demonstrated remarkable financial performance in 2024 and projects continued robust growth in the coming year. The company's strategic initiatives, including global market expansion and product development, position it for significant potential revenue increases.
For the fiscal year 2024, Kamada achieved an annual revenue of $161 million, representing a 13% increase from the previous year. The company's adjusted EBITDA rose 42% to $34.1 million, highlighting improved operational efficiency. Net income reached $14.5 million, a substantial 75% increase compared to the prior year.
Management anticipates maintaining this momentum, forecasting total 2025 revenue between $178 million and $182 million – representing approximately 12% year-over-year growth. Key revenue drivers include six FDA-approved plasma-derived specialty therapies, with particular emphasis on products like KEDRAB®, a human rabies immune globulin, and CYTOGAM®, an immunoglobulin that prevents cytomegalovirus complications in organ transplant patients.
The company's expansion strategy encompasses multiple dimensions. Notably, Kamada secured a $25 million contract to supply critical medical treatments in South America from 2025 through 2027, signaling its growing international market presence. Additionally, the company plans to launch biosimilar products in Israel, with expectations of generating $15-20 million in annual sales within five years.
A significant development is Kamada's ongoing phase 3 trial for an inhaled alpha-1 antitrypsin (AAT) therapy, targeting a genetic disorder potentially representing a $2 billion market opportunity. The company is also expanding its plasma collection operations, opening a third facility in San Antonio, Texas, which is expected to contribute $8-10 million in annual revenue and reduce reliance on third-party plasma suppliers.
The strategic approach extends to potential mergers, acquisitions, and business development opportunities. CEO Amir London emphasized the company's commitment to identifying synergistic product portfolios that can accelerate revenue growth while ensuring long-term sustainability.
Kamada's performance underscores the critical role of plasma-derived medicines in addressing rare and serious medical conditions. By focusing on specialized therapeutics and maintaining a disciplined operational strategy, the company demonstrates significant potential for continued growth and market expansion.
